Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

90.19 +0.43 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Prices $3.5 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
From Gilead Sciences, Inc.
Via Business Wire
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
Via ACCESSWIRE
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Engagements
From Gilead Sciences, Inc.
Via Business Wire
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Third Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
From Gilead Sciences, Inc.
Via Business Wire
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital. 
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
From Gilead Sciences, Inc.
Via Business Wire
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.